CTEV · Claritev Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 7, 2026TL;DR. Claritev posted Q2 revenue of $257.5M (up 6.6% YoY) with Adjusted EBITDA of $155.8M, raised full-year revenue guidance to $1.00B–$1.02B and Adjusted EBITDA to $610M–$620M, and reported $74M of H1 bookings tracking ahead of its $100M full-year target, though GAAP results remain in a net loss and Adjusted EBITDA margin compressed to 60.5%.
- + Q2 revenue grew 6.6% YoY to $257.5M, the fifth straight quarter of YoY growth and the highest in 15 quarters
- + Q2 free cash flow of $54.6M was up 49% YoY and operating cash flow of $92.7M was up 51%
- + Q2 Adjusted EBITDA of $155.8M increased 1.1% YoY and was the strongest in 13 quarters on an absolute dollar basis
- − Adjusted EBITDA margin compressed to 60.5% from 63.8% in Q2 2025
- − Q2 network revenue declined YoY on a reported basis due to lapping a $5.4M one-time item
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Cash Conversion Ratio non-GAAP | 42% | Six Months Ended June 30, 2026 | — |
| Adjusted earnings per share non-GAAP | $1.41 | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $302.71M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 60.5% | Q2 2026 | — |
| Adjusted net income non-GAAP | $23.98M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss -59.23M
+85.91M Amortization of intangible assets
+2.57M Legal expenses associated with antitrust matters
+309K Loss on disposal of assets, including right-of-use assets
+9.25M Transformation costs
+25K Other expenses, net
+0K Integration expenses
+0K Transaction costs related to refinancing transaction
+9.53M Stock-based compensation, including cRSUs
-24.39M Estimated tax effect of adjustments
= Adjusted net income 23.98M
|
|||
| EBITDA | $251.84M | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | -$37.96M | Six Months Ended June 30, 2026 | — |
| Unlevered Free Cash Flow non-GAAP | $126.25M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTEV
this stock
Claritev Corp
|
$363.18M | -42.3% | +3.7% | — | 5.6% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +27.0% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +41.5% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +65.6% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTEV | +9.8% | -35.8% | +36.1% | +16.6% | -42.3% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +8.6% | -36.4% | +24.5% | +15.0% | -55.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.